Drugs / UMIKIBART
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02499224 | Jul 2015 → Jul 2018 | cancer | CellabMED | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04368507 | Aug 2019 → Dec 2021 | colorectal cancer | CellabMED | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UMIKIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068187 ↗ |
| Known as | YYB101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04368507 ↗ |
| Action | Inhibit | “Hepatocyte Growth Factor (HGF)-Neutralizing” NCT04368507 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody against hepatocyte growth factor (HGF)” PMID 32536979 ↗ Jun 2020 |
| Route | Intravenous | “YYB101 was administered intravenously to refractory cancer patients” PMID 32536979 ↗ Jun 2020 |
| Target | HGF | “a humanized monoclonal antibody against hepatocyte growth factor (HGF)” PMID 32536979 ↗ Jun 2020 |